Pharmaceutical Business Intelligence

  • Find generic sources and suppliers
  • Formulary management
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

Details for Patent: 4,894,369

« Back to Dashboard

Summary for Patent: 4,894,369

Title: Novel 2.beta.-morpholino-androstane derivatives
Abstract:Compounds having the formula: ##STR1## wherein R.sub.1 is H or an optionally substituted acyl group having 1-12 carbon atoms, R.sub.2 is H or an acyl group having 1-12 carbon atoms and R.sub.3 is C, N--CH.sub.3 or a direct bond; and mono- or bisquaternary ammonium compounds thereof and acid addition salts of the non- or mono-quaternary ammonium compounds. Process for the preparation of these compounds. Compositions comprising at least one of the above compounds as the active ingredient. The compounds are favorable neuromuscular blocking agents.
Inventor(s): Sleigh; Thomas (Wishaw, GB6), Savage; David S. (New Mearns, GB6), Carlyle; Ian C. (Hamilton, GB6)
Assignee: Akzo N.V. (Arnhem, NL)
Application Number:07/181,139
Patent Claim Types:
see list of patent claims
Compound; Composition; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 4,894,369

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8708886Apr 14, 1987

International Patent Family for Patent: 4,894,369

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria79631► Subscribe
Australia1457088► Subscribe
Australia608313► Subscribe
Canada1291117► Subscribe
Germany19575040► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.